NovoCure Ltd (NVCR)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net revenues | 158,805 | 154,994 | 155,095 | 150,356 |
| Cost of revenues | 41,472 | 38,521 | 35,372 | 34,654 |
| Gross profit | 117,333 | 116,473 | 119,723 | 115,702 |
| Sales and marketing | 57,066 | 55,792 | 59,830 | 56,616 |
| Research, development and clinical studies | 55,833 | 53,777 | 51,882 | 54,955 |
| General and administrative | 43,955 | 44,769 | 40,103 | 37,711 |
| Total operating costs and expenses | 156,854 | 154,338 | 151,815 | 149,282 |
| Operating income (loss) | -39,521 | -37,865 | -32,092 | -33,580 |
| Financial income (expenses), net | 4,542 | 7,570 | 10,507 | 10,851 |
| Income (loss) before income tax | -34,979 | -30,295 | -21,585 | -22,729 |
| Income tax | 5,160 | 4,024 | 8,985 | 10,646 |
| Net income (loss) | -40,139 | -34,319 | -30,570 | -33,375 |
| Basic net income (loss) per ordinary share (in usd per share) | -0.36 | -0.31 | -0.28 | -0.31 |
| Diluted net income (loss) per ordinary share (in usd per share) | -0.36 | -0.31 | -0.28 | -0.31 |
| Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | 111,572,191 | 110,281,832 | 108,247,716 | 107,700,284 |
| Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | 111,572,191 | 110,281,832 | 108,247,716 | 107,700,284 |